Treatment of breast cancer with fibroblasts transfected with DNA from breast cancer cells

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6934-6941

  De Zoeten, Edwin ^a   Carr Brendel, Victoria ^a   Markovic, Dubravka ^a   Taylor Papadimitriou, Joyce ^b   Cohen, Edward P ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENE PRODUCT; H2 ANTIGEN; HYGROMYCIN; INTERLEUKIN 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; DNA TRANSFECTION; FIBROBLAST; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE; DNA, NEOPLASM; EPITOPES; FIBROBLASTS; H-2 ANTIGENS; INTERLEUKIN-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SURVIVAL ANALYSIS; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINES, DNA;

EID: 0033152752     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
2. Boon, T. 1993. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int. J. Cancer 54:177.
3. Boon, T. 1992. Toward a genetic analysis of tumor rejection antigens. Adv. Cancer Res. 58:177.
4. Storkus, W. J., H. J. Zeh III, M. J. Maeurer, R. D. Salter, and M. T. Lotze. 1993. Identification of human melanoma peptides recognized by class I restricted tumors infiltrating T lymphocytes. J. Immunol. 151:3719.
5. Disis, M. L., and M. A. Cheever. 1997. HER-Z/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71:343.
6. Brasseur, F., M. Marchand, R. Vanwijk, M. Herin, B. Lethe, P. Chomez, and T. Boon. 1992. Human gene MAGE-1 which codes for a tumor rejection antigen is expressed in some breast tumors. Int. J. Cancer 52:839.
7. Fujie, T., M. Mori, H. Ueo, K. Sugimachi, and T. Akiyoshi. 1997. Expression of MAGE and BAGE genes in Japanese breast cancers. Ann. Oncol. 8:369.
8. Horgan, P. G., J. Byrne, J. O'Donoghue, E. Mooney, H. Grimes, and H. F. Given. 1997. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer, Jr. J. Med. Sci. 166:215.
9. Domenenech, N., R. A. Henderson, and O. J. Finn. 1995. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155:4766.
10. Jerome, K. R., N. Domenech, and O. J. Finn. 1992. Tumor-specific cytotoxic T lymphocyte clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin cDNA. J. Immunol. 151:1644.
11. Wooster, R., A. Cleton-Jansen, N. Collins, J. Mangion, R. Cornelius, C. Cooper, B. A. Gusterson, B. A. T. Ponder, A. van Deimling, O. D. Wiestler, et al. 1994. Instability of short tandem repeats (microsatellites) in human cancers. Nat. Genet. 6:152.
12. Merlo, A., M. Mabry, E. Gabrielson, R. Vollmer, S. B. Baylin, and D. Sidransky. 1994. Frequent microsatellite instability in primary small lung cancer. Cancer Res. 54:2098.
13. Orth, K., J. Hung, A. Gazdar, A. Bowcock, J. M. Mathis, and J. Sambrook. 1994. Genetic instability in human ovarian cancer cell lines. Proc. Natl. Acad. Sci. USA 91:9495.
14. + tumor cells. Cell 75:1227.
15. Shibata, D., M. A. Peinado, Y. Ivonov, S. Malkhosyan, and M. Perucho. 1994. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat. Genet. 6:273.
16. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, and S. A. Rosenberg. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213.
17. Kim, C. J., T. Prevette, J. Cormier, W. Overwijk, M. Roden, and N. P. Restifo. 1997. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother. 20:276.
18. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
19. Tuting, T., W. J. Storkus, and M. T. Lotze. 1997. Gene-based strategies for the immunotherapy of cancer. J. Mol. Med. 75:478.
20. Shurin, M. R., C. Esche, J. M. Peron, and M. T. Lotze. 1997. Antitumor activities of IL-12 and mechanisms of action. Chem. Immunol. 68:153.
21. Nabel, G. J., D. Gordon, D. K. Bishop, B. J. Nickoloff, Z.-Y. Yang, A. Aruga, M. J. Cameron, and E. G. Nabel. 1996. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA 93:15388.
22. Kawakami, Y., and S. A. Rosenberg. 1997. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. 14:173.
23. Cavallo, F., F. D. Pierro, M. Giovarelli, A. Gulino, A. Vacca, A. Stoppacciaro, M. Form, A. Modesti, and G. Forni. 1993. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53:5067.
24. Russell, S. J., S. A. Eccles, C. L. Flemming, C. A. Johnson, and M. K. L. Collins. 1991. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer 47:244.
25. Chakravarty, P. K., H. Fuji, M. M. Abu-hadid, S.-C. Hsu, and A. K. Sood. 1992. Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected LI210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression: potential therapeutic implications. Cancer Immunol. Immunother. 35:347.
26. Kim, T. S., S. J. Russell, M. K. L. Collins, and E. P. Cohen. 1993. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of tumor-bearing mice with melanoma. Int. J. Cancer 55:865.
27. Kim, T. S., and E. P. Cohen. 1994. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2 secretion and expression of melanoma-associated antigens stimulates predetermined classes of anti-melanoma effector cells. J. Immunother. 16:24.
28. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
29. Mullen, C. A., M. M. Coale, A. T. Levy, W. G. Stetler-Stevenson, L. A. Liotta, S. Brandt, and R. M. Blaese. 1992. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased melastatic potential. Cancer Res. 52:6020.
30. Aoki, T., K. Tashiro, S.-I. Miyatake, T. Kinashi, T. Nakano, Y. Oda, H. Kikuchi, and T. Honjo. 1992. Expression of marine interleukin 7 in a murine glioma cell-line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89:3850.
31. Tahara, H., H. J. Zeh, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. F. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182.
32. Asher, A. L., J. J. Mule, and A. Kasid. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3227.
33. Blankenstein, T., Z. Qin, K. Uberla, W. Muller, H. Rosen, H.-D. Volk, and T. Diamantstein. 1991. Tumor suppression after tumor cell-targeted tumor necrosis factor a gene transfer. J. Exp. Med. 173:1047.
34. Ferrantini, M., E. Proietti, L. Santodonato, L. Gabriele, M. Peretti, I. Plavec, F. Meyer, T. Kaido, I. Gresser, and F. Bellardelli. 1993. α1-interferon gene transfer into melastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor by means of interferon-producing cells. Cancer Res. 53: 1107.
35. Gansbacher, B., R. Bannerji, B. Daniels, K. Zier, K. Cronin, and E. Gilboa. 1990. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:7820.
36. Columbo, M. P., G. Ferrari, A. Stoppacciaro, M. Parenza, M. Rodolfo, F. Mavilio, and G. Parmiam. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:889.
37. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1991. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
38. Bottazzi, B., S. Walter, D. Govoni, F. Colotta, and A. Mantovani. 1992. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148:1280.
39. d). Cancer Res. 47:3136.
40. Mandelboim, O., E. Vadai, M. Feldman, and L. Eisenbach. 1995. Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells. Gene Ther. 2:757.
41. Hui, K. M., T. F. Sim, T. T. Foo, and A.-A. Oei. 1989. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J. Immunol 143: 3835.
42. Ostrand-Rosenberg, S., A. Thakur, and V. Clements. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144:4068.
43. + T cells: ICAM-1 or B-7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J. Immunol. 155:45.
44. Wigler, M., A. Pellicer, S. Silverstein, R. Axel, G. Urlaub, and L. Chasin. 1979. DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proc. Natl. Acad. Sci. USA 76:1373.
45. Wigler, M., A. Pellicer, S. Silverstein, and R. Axel. 1978. Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor. Cell 14:725.
46. Mendersohn, C., B. Johnson, K. A. Lionetti, P. Nobis, E. Wimmer, and V. R. Racaniello. 1986. Transformation of a human poliovirus receptor gene into mouse cells. Proc. Natl. Acad. Sci. USA 83:7845.
47. Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978. T-cell growth factor: parameters of production and quantitative microassay for activity. J. Immunol. 120:2027.
48. Allen, H., D. Wraith, P. Pala, B. Askonas, and R. A. Flavell. 1984. Domain interactions of H-2 class I antigens alter cytotoxic T-cell recognition sites. Nature 309:279.
49. Vile, R., and I. Hart. 1993. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53:962.
50. Wilde, D. B., P. Marrack, J. Kappler, D. P. Dialnas, and F. W. Filch. 1983. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J. Immunol. 131:2178.
51. Sarmiento, M., A. L. Glasebrook, and F. W. Fitch. 1980. IgG or IgM monoclonal antibodies bearing Lyt2 antigen block T cell-mediated cylolysis in the absence of complement. J. Immunol. 125:266.
52. Sugden, B., K. Marsh, and J. Yates. 1985. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol. Cell. Biol. 5:410.
53. Kundig, T. M., M. F. Bachmann, C. DiPaolo, J. J. L. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhleke, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343.
54. Schoenberger, S. P., L. E. Jonges, R. J. D. Mooijaart, F. Hangers, R. E. M. Toes, W. M. Kast, C. J. M. Melief, and R. Offringa. 1998. Efficient direct priming of tumor-specific cytotoxic T lymphocytes in vivo by an engineered APC. Cancer Res. 58:3094.
55. Kim, T. S., W. S. Xu, E. de Zoeten, and E. P. Cohen. 1995. Immunization with interleukin-2/interferon-γ double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res. 5:217.
56. Kim, T. S., and E. P. Cohen. 1994. MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma associated antigens. Cancer Immunol. Immunother. 38:185.
57. De Zoeten, E. F., V. Carr-Brendel, and E. P. Cohen. 1998. Resistance to melanoma in mice immunized with semi-allogeneic fibroblasts transfected with DNA from mouse melanoma cells. J. Immunol. 160:2915.